This article is an erratum on:
CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity
An Erratum on
CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.
By Baumgaertner P, Schmidt J, Costa-Nunes C-M, Bordry N, Guillaume P, Luescher I, Speiser DE, Rufer N and Hebeisen M (2022) Front. Immunol. 13:973986. doi: 10.3389/fimmu.2022.973986
An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Lausanne”.
The original version of this article has been updated.
Keywords: cancer immunotherapy, vaccine peptide, melan-A/MART-1, NY-ESO-1, peptide-HLA binding affinity, TCR-peptide-MHC affinity, human CD8 T cells
Citation: Frontiers Production Office (2023) Erratum: CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity. Front. Immunol. 14:1178295. doi: 10.3389/fimmu.2023.1178295
Received: 02 March 2023; Accepted: 02 March 2023;
Published: 14 March 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn